Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT05830110
Active, not recruiting Not applicable

Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease

NCT05830110 · tracked via the Priya Life Science USA tracker
Sponsor
Synergic Medical Technologies, Inc
Phase
Not applicable
Started
2023-03-01
Last updated
2026-04-24

Condition(s) studied

Parkinson's Disease

Investigational drug(s) / intervention(s)

Active Vibrotactile Coordinated ResetSham vibrotactile coordinated reset

Active Vibrotactile Coordinated Reset: Gloves providing vibrotactile coordinated reset stimulation

Sham vibrotactile coordinated reset: Gloves providing sham vibrotactile coordinated reset stimulation

Study summary

The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses a novel stimulation pattern to disrupt the pathophysiological mechanism that is responsible for PD symptoms and thus restore motor function.

Eligibility

Sex
ALL
Min age
45 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * between the ages 45 and 90 * diagnosis of bilateral, moderate stage idiopathic PD * qualify for EEG procedures Exclusion Criteria: * on dopamine agonist medications and exhibiting compulsive behaviors

Primary outcome measure(s)

  • Movement Disorder Society - Change in Universal Parkinson Disease Rating Scale (MDS-UPDRS) — baseline, 2 months, 4 months
    Change in MDS-UPDRS score using Part 3 of the scale.

Trial sites (1)

FacilityCityRegionStatus
Synergic Medical Technologies Eugene Oregon

More Synergic Medical Technologies, Inc. trials in the USA

Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease 2 Active, not recruiting

Other trials for the same condition

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications Recruiting
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry Recruiting
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD Active, not recruiting
GDNF Gene Therapy for Parkinson's Disease Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05830110 on ClinicalTrials.gov ↗ ← All trials in the USA